Empagliflozin-induced lipidome remodeling in type 2 diabetes: mechanistic insights and translational perspectives
Authors' conclusion
The discovery of LPCs as potential markers of empagliflozin's effect opens new avenues for developing pharmacodynamic biomarkers and understanding the metabolic mechanisms of action, including the relationship between lipid metabolism and kidney health.
Study context
- Population
- Patients with T2D
- Comparison
- Empagliflozin vs placebo
Methodological detailsrandomized, placebo-controlled, untargeted lipidomics, sparse group LASSO regression
- Randomized
- Placebo-controlled
- Untargeted lipidomics
- Sparse group LASSO regression
Primary result
As reported in the abstract
Plasma lipidome alterations with empagliflozin · after one and twelve weeks of treatment
- Significant and reproducible alterations in specific lipid classes, most notably lysophosphatidylcholines (LPCs)
- Lipid profile changes correlated with estimated glomerular filtration rate (eGFR), uric acid and blood pressure
Original publication
Empagliflozin-induced lipidome remodeling in type 2 diabetes: mechanistic insights and translational perspectives. Cardiovasc Diabetol. Published 4 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →